Search
Talnetant
go.drugbank.com/drugs/DB06429InvestigationalTalnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential
Categories: Heterocyclic Compounds, 2-Ring, Receptors, Neurokinin-3, antagonists & inhibitorsEnzastaurin
go.drugbank.com/drugs/DB06486InvestigationalEnzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
Categories: Heterocyclic Compounds, 2-RingR-1487
go.drugbank.com/drugs/DB06518ExperimentalSalts: R-1487 hydrochlorideCategories: Heterocyclic Compounds, 1-RingMitemcinal
go.drugbank.com/drugs/DB06587InvestigationalMitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsVicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesClazosentan
go.drugbank.com/drugs/DB06677InvestigationalCategories: Receptor, Endothelin A, Heterocyclic Compounds, 1-RingClevudine
go.drugbank.com/drugs/DB06683InvestigationalSynonyms: 2'-Fluoro-5-methyl-beta-L-arabinofuranosyluracil, L-FMAUCategories: Heterocyclic Compounds, 1-RingVilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622].
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingLaquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEthanolamine oleate
go.drugbank.com/drugs/DB06689ApprovedEthanolamine oleate is a mild sclerosing agent. … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.
Categories: Compounds used in a research, industrial, or household setting